New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
07:04 EDTOMEROmeros receives FDA approval for Omidria
Omeros announced that the FDA has approved Omidria 1%/0.3% for use during cataract surgery or intraocular lens replacement to maintain pupil size by preventing intraoperative miosis and to reduce postoperative pain. The approval comes with no post-marketing commitments other than the previously agreed study of Omidria for use in pediatric patients, which, if successfully completed, makes the drug eligible for an additional six months of marketing exclusivity in the U.S. With FDA approval of Omidria, Omeros is completing preparations for a late summer/early fall 2014 U.S. product launch.
News For OMER From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 16, 2015
16:23 EDTOMEROmeros sees FY15 OpEx $110M-$120M
For 2015, the company anticipates that operating expenses will be in the $110M-$120M range with non-cash expenses of approximately $15M. This guidance is largely based on the continued preparations for the full-scale U.S. launch of Omidria as well as the continued development of the company's product pipeline.
16:22 EDTOMEROmeros reports Q4 EPS (61c) with items, consensus (62c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use